Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.18B P/E - EPS this Y 6.10% Ern Qtrly Grth -
Income -200.07M Forward P/E -4.99 EPS next Y -5.80% 50D Avg Chg 3.00%
Sales 11.76M PEG - EPS past 5Y - 200D Avg Chg -6.00%
Dividend N/A Price/Book 2.32 EPS next 5Y - 52W High Chg -56.00%
Recommedations 1.80 Quick Ratio 17.02 Shares Outstanding 83.92M 52W Low Chg 47.00%
Insider Own 7.62% ROA -19.48% Shares Float 66.94M Beta 1.70
Inst Own 86.89% ROE -34.78% Shares Shorted/Prior 15.69M/14.10M Price 19.12
Gross Margin - Profit Margin - Avg. Volume 604,911 Target Price 32.13
Oper. Margin -1,048.76% Earnings Date - Volume 479,433 Change -1.54%
About Verve Therapeutics, Inc.

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Verve Therapeutics, Inc. News
05/03/24 Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04/25/24 Why Investors Need to Take Advantage of These 2 Medical Stocks Now
08:50 AM After a Serious Setback, Is Verve Therapeutics a Buy?
04/04/24 Biotech Stock Roundup: IRON, VERV Down on Study Updates, BMYs Drug News & More
04/03/24 Verve (VERV) Pauses Enrollment in Cholesterol Study, Stock Falls
04/02/24 Verve Plunges To Record Low After Cholesterol-Lowering Gene Editor Causes Side Effects
04/02/24 UPDATE 1-Verve Therapeutics pauses enrollment in early-stage gene therapy study for high cholesterol levels
04/02/24 Verve Therapeutics pauses enrollment in early-stage gene therapy study for high cholesterol levels
04/02/24 Verve Therapeutics Announces Updates on its PCSK9 Program
04/02/24 Verve pauses base editing trial, shifts strategy after treatment side effect
03/21/24 3 Stocks That Could Be the Next Big Thing in Gene Editing
02/29/24 New Forecasts: Here's What Analysts Think The Future Holds For Verve Therapeutics, Inc. (NASDAQ:VERV)
02/28/24 Verve Therapeutics Full Year 2023 Earnings: Beats Expectations
02/27/24 Verve Therapeutics Inc (VERV) Reports Progress and Financials for Q4 and Full Year 2023
02/27/24 Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
02/19/24 3 Biotech Stocks to Buy That Have CRISPR-Like Breakthrough Potential
02/15/24 Relay Therapeutics, Inc. (RLAY) Moves 10.0% Higher: Will This Strength Last?
02/13/24 3 Gene Editing Stocks With Unprecedented Surge Potential
02/12/24 2 Risky Gene-Editing Stocks to Buy in the New Bull Market if You Dare
02/01/24 Verve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
VERV Chatroom

User Image BarneyR Posted - 2 days ago

$BEAM $EDIT $NTLA $CRSP $VERV These are all high beta stocks, meaning they're predicted to react at multiple times an index's movement. You can tell they're being suppressed when every bit of info about delayed fed interest rate drops or a red index day is used to drive them down. And every bit of good news bolstering the case for lower interest rates and a higher index results in these shares barely keeping up with the index rise (NASDAQ up nearly 2% today). High beta down, low beta up. It's clear they're being held down by MMs and short interest. It can't last much longer, approvals keep coming, revenue is building, improving ERs and positive study results are highlighting the promise of gene therapy. Longs are destined to prevail.

User Image butc Posted - 2 days ago

$VERV bwahahahahah fkn garbage

User Image BarneyR Posted - 2 days ago

$CRSP $BEAM $NTLA $VERV $EDIT There will come a time when volume and momentum overcome these aholes and their algos, who do everything in their power to blunt any upward movement of the gene pool.

User Image butc Posted - 2 days ago

$VERV said pump not dump it

User Image butc Posted - 2 days ago

$VERV pump it into er

User Image butc Posted - 3 days ago

$VERV what a win today fkn garbage

User Image butc Posted - 3 days ago

$VERV cmon u can do it go red

User Image butc Posted - 3 days ago

$VERV will close red as always fkn garbage on a such green day

User Image butc Posted - 3 days ago

$VERV what a dumpster

User Image butc Posted - 3 days ago

$VERV move up u fkn pos

User Image butc Posted - 3 days ago

$VERV fkn garbage

User Image Trending__Now Posted - 4 days ago

$VERV Why I'm back in? LOL, I hope Lilly puts an offer in at twice the price. It's a steal. Selling for less than cash on hand?

User Image AdiDasRom Posted - 4 days ago

$VERV

User Image BarneyR Posted - 04/30/24

$BEAM $CRSP $EDIT $NTLA $VERV Pigs at the trough.

User Image butc Posted - 04/29/24

$VERV total garbage

User Image butc Posted - 04/29/24

$VERV will close red no worries

User Image butc Posted - 04/26/24

$VERV what a junk

User Image Market_Luther_King Posted - 04/26/24

$VERV I want to buy in here but everything in the pipeline is so early stage that I think this will continue to trend downwards for the time being. I'll keep my eye on it though.

User Image BarneyR Posted - 04/26/24

$CRSP $BEAM $NTLA $VERV $EDIT These hedgehogs are insatiable pigs and they'll deserve every bit of the comeuppance headed their way.

User Image butc Posted - 04/25/24

$VERV trash

User Image russellkbrett Posted - 04/25/24

@Do_The_Opposite Not just $EDIT. The whole group. $CRSP and $BEAM also down 8 consecutive weeks following previous ER beats and positive reactions/analyst upgrades on the shares. BEAM down -57% from its ($49.50) Feb earnings high. EDIT down -56% and trading at cash value. $VERV trading below cash value with 28% of float now short and there hasn't been a single analyst downgrade this whole slide down. Incredible.

User Image butc Posted - 04/25/24

$VERV cmon pump this shit into er

User Image BarneyR Posted - 04/25/24

$CRSP $BEAM $NTLA $VERV $EDIT The Regeneron/Mammoth deal didn't make all other gene editors less valuable today, it made them more valuable. There's only a handful of dance partners in the gene editing business and big pharma, knowing that, is going to be more eager (with today's news) to solidify relationships with viable experts.

User Image MagisterofMarkets Posted - 04/25/24

$PRME $CRBU $VERV $BEAM $NTLA cant stop buying, I guess I’m a sucker for pain

User Image BarneyR Posted - 04/25/24

$BEAM $CRSP $VERV $NTLA $VERV Instead of considering Regeneron's deal with Mammoth as an indicator of the validity of gene therapy, the brilliant goobers on Wall Street think "Oh, this is going to be competition for existing companies" and use it as an excuse to drop the share price of the entire group. Idiots.

User Image MagisterofMarkets Posted - 04/25/24

$VERV i remember when this was at $70 and thinking “I’ll hold til $100”.

User Image BarneyR Posted - 04/25/24

$CRSP $BEAM $NTLA $VERV $EDIT Well of course we must thrash biotech, the whipping boy of Wall Street. Bloody game for these scumbags, shaking shares loose by squeezing the rubes.

User Image butc Posted - 04/25/24

$VERV down down down down, down down da down down down down down dowm da down, down down down down...

User Image BarneyR Posted - 04/24/24

$CRSP $BEAM $VERV $EDIT $NTLA Welcome to another day of the Wall Street shiteshow, where algos and bots drive SPs up and down for fun and profit while fleecing investors. Same as Las Vegas casinos, house always maintains the advantage.

User Image butc Posted - 04/24/24

$VERV fkn pos just give me 8 usd that I can bail out ot this garbage

Analyst Ratings
Stifel Buy Apr 3, 24
RBC Capital Outperform Feb 28, 24
Cantor Fitzgerald Neutral Sep 13, 23
Cantor Fitzgerald Neutral Aug 29, 23
Guggenheim Buy Aug 15, 23
Credit Suisse Neutral Aug 11, 23
Canaccord Genuity Buy Jun 16, 23
RBC Capital Outperform May 16, 23
Canaccord Genuity Buy Apr 13, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Bellinger Andrew CSO & CMO CSO & CMO Dec 14 Option 2.87 36,000 103,320 42,629 12/16/22
Bellinger Andrew CSO & CMO CSO & CMO Dec 01 Sell 22.95 865 19,852 6,629 12/02/22
Yeshwant Krishna Director Director Nov 04 Sell 32 48,583 1,554,656 4,260,047 11/08/22
GV 2017 GP, L.L.C. Other Other Nov 04 Sell 32 97,166 3,109,312 4,260,047 11/08/22
GV 2017 GP, L.L.C. Other Other Nov 02 Sell 34.52 156,440 5,400,309 4,308,630 11/04/22
Yeshwant Krishna Director Director Oct 31 Sell 38.69 85,659 3,314,147 4,386,850 11/02/22
Ashe Andrew D. See Remarks See Remarks Aug 25 Option 1.91 95,787 182,953 266,509 08/29/22
Kathiresan Sekar Chief Executive Offi.. Chief Executive Officer Aug 10 Option 1.39 50,000 69,500 367,839 08/11/22
Kathiresan Sekar Chief Executive Offi.. Chief Executive Officer Aug 10 Sell 29.9 50,000 1,495,000 317,839 08/11/22
Bellinger Andrew CSO & CMO CSO & CMO Jul 20 Option 1.39 20,000 27,800 26,629 07/22/22
Bellinger Andrew CSO & CMO CSO & CMO Jul 20 Sell 34.9 20,000 698,000 6,629 07/22/22
Kathiresan Sekar Chief Executive Offi.. Chief Executive Officer Jul 19 Option 1.39 50,000 69,500 367,839 07/21/22
Kathiresan Sekar Chief Executive Offi.. Chief Executive Officer Jul 19 Sell 29.9 50,000 1,495,000 317,839 07/21/22
Bellinger Andrew CSO & CMO CSO & CMO Jul 13 Option 1.48 10,000 14,800 16,629 07/15/22
Bellinger Andrew CSO & CMO CSO & CMO Jul 13 Sell 24.9 10,000 249,000 6,629 07/15/22
FMR LLC 10% Owner 10% Owner Jul 12 Sell 21.01 163,000 3,424,630 570,729 07/14/22
Kathiresan Sekar Chief Executive Offi.. Chief Executive Officer Mar 18 Option 2.87 69,674 199,964 477,525 03/22/22
ADELMAN BURT A Director Director Mar 15 Buy 21.3838 4,000 85,535 8,700 03/17/22
FMR LLC 10% Owner 10% Owner Mar 09 Sell 29.01 3,971 115,199 825,723 03/11/22
FMR LLC 10% Owner 10% Owner Feb 09 Sell 29.46 13,190 388,577 829,694 02/11/22
FMR LLC 10% Owner 10% Owner Feb 01 Sell 29.04 35,574 1,033,069 842,884 02/03/22
FMR LLC 10% Owner 10% Owner Jan 26 Sell 30.41 158,836 4,830,203 878,458 01/28/22
Bellinger Andrew Chief Scientific Off.. Chief Scientific Officer Dec 22 Option 1.48 15,000 22,200 20,000 12/27/21
Bellinger Andrew Chief Scientific Off.. Chief Scientific Officer Dec 22 Sell 38.47 15,000 577,050 5,000 12/27/21
Kathiresan Sekar Chief Executive Offi.. Chief Executive Officer Dec 22 Option 1.39 114,000 158,460 463,536 12/27/21
Kathiresan Sekar Chief Executive Offi.. Chief Executive Officer Dec 22 Sell 38.89 114,000 4,433,460 406,536 12/27/21